HF 5147, titled “Income and corporate franchise tax provisions modified, and addition for pharmaceutical marketing expenses required,” would amend Minnesota’s individual income and corporate franchise tax laws. It would require certain pharmaceutical marketing expenses deducted under federal tax law to be added back when calculating Minnesota tax. The bill’s stated goal is to require that addback; the bill is at first reading and is not law.
No cost or revenue estimate is available in the supplied material.
Bills on related subjects, starting with Minnesota.
Lawmakers would require a Minnesota tax add-back for direct-to-consumer pharmaceutical marketing expenses, starting with the 2027 tax year.
Status
Referred to Taxes
A bill would cap prices for Medicare-negotiated drugs in Minnesota and require reimbursements at the higher of the cap or NADAC, with withdrawal penalties; effective January 1, 2027.
Status
Authors added Berg; Kozlowski; Pursell; Jordan; Kraft; Johnson, P.; Freiberg; Virnig; Liebling; Gottfried; Youakim; Greenman; Feist; and Falconer
Senate bill would apply Medicare price rules to Minnesota drug sales, with a price cap and reimbursement rules starting January 1, 2027.
Status
Referred to Health and Human Services
A bill would award a one-time rebate to eligible vehicle owners and switch registration tax calculations to MSRP-based schedules starting Jan 1, 2027.
Status
Introduction and first reading, referred to Transportation Finance and Policy